Impact of statins on long-term prognosis in patients with ischemic chronic heart failure with renal dysfunction
DOI:
https://doi.org/10.14739/2310-1210.2020.2.200556Keywords:
heart failure, statins, kidneyAbstract
The aim of the study was to investigate the long-term effects of the inclusion in the basic therapy of statins in patients with ischemic chronic heart failure with renal dysfunction.
Materials and methods. The study, after obtaining informed consent, involved 383 patients with ischemic CHF of II-IV functional class, median age – 59 [53; 66] years (men – 81.9 %). Patients were divided into two groups: group 1 – 140 patients (81.4 % of men) with ischemic CHF with reduced EF (HFrEF) and renal dysfunction, group 2 – 243 patients (82.3 % of men) with ischemic CHF with preserved EF (HFpEF) and renal dysfunction. As a hypolipidemic agent, patients received atorvastatin or rosuvastatin.
Results. It was found that the inclusion of statins in the basic therapy for patients with HFrEF and renal dysfunction leads to a 51 % reduction in the risk of cumulative endpoint (relative risk (RR of 0.49; 95 % confidence interval (CI) of 0.26–0.91; P < 0.05) with preference for atorvastatin group versus rosuvastatin (RR 0.37; 95 % CI 0.21–0.69; P < 0.001). In patients with HFpEF and renal dysfunction using statins in the basic therapy, there was only a tendency to reduce the risk of cumulative endpoint (RR 0.62; 95 % CI 0.15–2.51; P > 0.05).
Conclusions. In patients with ischemic CHF with reduced EF and renal dysfunction, the inclusion of statins (mainly atorvastatin) in the complex treatment is associated with a reduced risk of developing a cumulative endpoint, re-hospitalization for acute HF decompensation. Patients with ischemic CHF with preserved EF in the presence of renal dysfunction, atorvastatin should be given preference in the choice of hypolipidemic drug in order to reduce the risk of achieving cumulative endpoint.
References
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G. M. C., Ruilope, L. M., Ruschitzka, F., … van der Meer, P. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), 2129–2200. https://doi.org/10.1093/eurheartj/ehw128
Takahama, H., & Kitakaze, M. (2017). Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets. American Journal of Physiology-Heart and Circulatory Physiology, 313(4), H715–H721. https://doi.org/10.1152/ajpheart.00215.2017
Lashkul, D. A. (2016). Predyktory rozvytku nespryiatlyvykh podii u khvorykh na khronichnu sertsevu nedostatnist ishemichnoho henezu zi znyzhenoiu fraktsiieiu vykydu livoho shlunochka ta nyrkovoiu dysfunktsiieiu [Predictors of adverse events in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction]. Zaporozhye medical journal, (3), 4-9. https://doi.org/10.14739/2310-1210.2016.3.76914 [in Ukrainian].
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., Reiner, Ž., Riccardi, G., Taskinen, M.-R., Tokgozoglu, L., Verschuren, W. M. M., Vlachopoulos, C., Wood, D. A., & Zamorano, J. L. (2016). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 37(39), 2999-3058. https://doi.org/10.1093/eurheartj/ehw272
Katsiki, N., Doumas, M., & Mikhailidis, D. P. (2016). Lipids, Statins and Heart Failure: An Update. Current Pharmaceutical Design, 22(31), 4796-4806. https://doi.org/10.2174/1381612822666160701073452
Voronkov, L. H., Amosova, K. M., Bahrii, A. E., Dziak, H. V., Diadyk, O. I., Zharinov, O. Y., Kovalenko, V. M., Korkushko, O. V., Nesukai, O. H., Rudyk, Yu. S., & Parkhomenko, O. M. (2012). Rekomendatsii z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti (2012) [Recommendations for the diagnosis and management of chronic heart failure (2012)]. Sertseva nedostatnist, (3), 60-96. [in Ukrainian].
Zhang, L., Zhang, S., Jiang, H., Sun, A., Zou, Y., & Ge, J. (2010). Effects of Statin Treatment on Cardiac Function in Patients With Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Clinical Cardiology, 34(2), 117-123. https://doi.org/10.1002/clc.20821
Feinstein, M. J., Jhund, P., Kang, J., Ning, H., Maggioni, A., Wikstrand, J., Kjekshus, J., Tavazzi, L., McMurray, J., & Lloyd-Jones, D. M. (2015). Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. European Journal of Heart Failure, 17(4), 434-441. https://doi.org/10.1002/ejhf.247
Alehagen, U., Benson, L., Edner, M., Dahlström, U., & Lund, L. H. (2015). Association Between Use of Statins and Outcomes in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 8(2), 252-260. https://doi.org/10.1161/circheartfailure.114.001730
Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., & McMurray, J. J. V. (2015). The effect of statin therapy on heart failure events: A collaborative meta-analysis of unpublished data from major randomized trials. Atherosclerosis, 241(1), Article e21. https://doi.org/10.1016/j.atherosclerosis.2015.04.086
Mannheim, D., Herrmann, J., Bonetti, P. O., Lavi, R., Lerman, L. O., & Lerman, A. (2011). Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect. Atherosclerosis, 216(2), 283-291. https://doi.org/10.1016/j.atherosclerosis.2011.02.036
Marume, K., Takashio, S., Nagai, T., Tsujita, K., Saito, Y., Yoshikawa, T., & Anzai, T. (2019). Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Disease Report From the JASPER Study. Circulation Journal, 83(2), 357-367. https://doi.org/10.1253/circj.cj-18-0639
Yan, Y.-L., Qiu, B., Wang, J., Deng, S.-B., Wu, L., Jing, X.-D., Du, J.-L., Liu, Y.-J., & She, Q. (2015). High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ Open, 5(5), Article e006886. https://doi.org/10.1136/bmjopen-2014-006886
Al-Gobari, M., Le, H.-H., Fall, M., Gueyffier, F., & Burnand, B. (2017). No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials. PLOS ONE, 12(2), Article e0171168. https://doi.org/10.1371/journal.pone.0171168
Al-Gobari, M., Agrinier, N., Soudant, M., Burnand, B., & Thilly, N. (2019). Effects of Statins to Reduce All-Cause Mortality in Heart Failure Patients: Findings from the EPICAL2 Cohort Study. American Journal of Cardiovascular Drugs, 19(5), 497-508. https://doi.org/10.1007/s40256-019-00346-4
Oikawa, T., Sakata, Y., Nochioka, K., Miura, M., Tsuji, K., Onose, T., Abe, R., Kasahara, S., Sato, M., Shiroto, T., Takahashi, J., Miyata, S., & Shimokawa, H. (2018). Prognostic Impact of Statin Intensity in Heart Failure Patients With Ischemic Heart Disease: A Report From the CHART‐2 (Chronic Heart Failure Registry and Analysis in the Tohoku District Study. Journal of the American Heart Association, 7(6), Article e007524. https://doi.org/10.1161/jaha.117.007524
Zvizdić, F., Godinjak, A., Durak-Nalbantic, A., Rama, A., Iglica, A., Vucijak-Grgurevic, M., & Sokolovic, S. (2018). Impact of Different Types of Statins on Clinical Outcomes in Patients Hospitalized for Ischemic Heart Failure. Medical archives (Sarajevo, Bosnia and Herzegovina), 72(6), 401-405. https://doi.org/10.5455/medarh.2018.72.401-405
Lee, M.-S., Duan, L., Clare, R., Hekimian, A., Spencer, H., & Chen, W. (2018). Comparison of Effects of Statin Use on Mortality in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. The American Journal of Cardiology, 122(3), 405-412. https://doi.org/10.1016/j.amjcard.2018.04.027
Tsujimoto, T., & Kajio, H. (2018). Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease. International Journal of Cardiology, 255, 111-117. https://doi.org/10.1016/j.ijcard.2017.12.109
Gastelurrutia, P., Lupón, J., de Antonio, M., Urrutia, A., Díez, C., Coll, R., Altimir, S., & Bayes-Genis, A. (2012). Statins in Heart Failure: The Paradox Between Large Randomized Clinical Trials and Real Life. Mayo Clinic Proceedings, 87(6), 555-560. https://doi.org/10.1016/j.mayocp.2012.02.018
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
